PharmaEngine (ROCO:4162) Float Percentage Of Total Shares Outstanding: 0.00% (As of Jul. 12, 2026)


ROCO:4162 PharmaEngine Inc ROCO:4162
79 GF Score
Price NT$64.50
GF Value NT$115.42
Valuation Significantly Undervalued
! 3 Warning Signs
View Full Analysis

What is PharmaEngine Float Percentage Of Total Shares Outstanding?

PharmaEngine ROCO:4162 79 Float Percentage Of Total Shares Outstanding is 0.00% as of Jul. 12, 2026. GuruFocus rates ROCO:4162 with a GF Score™ of 79/100 and a GF Value™ of NT$115.42 (Significantly Undervalued). The stock has 3 warning signs investors should review.

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, PharmaEngine's float shares is 0.00 Mil. PharmaEngine's total shares outstanding is 143.68 Mil. PharmaEngine's float percentage of total shares outstanding is 0.00%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, PharmaEngine's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, PharmaEngine's Institutional Ownership is 3.93%.

ROCO:4162
79GF Score
PharmaEngine Inc ROCO:4162
Float Percentage Of Total Shares Outstanding is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PharmaEngine Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

PharmaEngine's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=0.00/143.68
=0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Float Percentage Of Total Shares Outstanding of 0.00% mean?
PharmaEngine (ROCO:4162) has a Float Percentage Of Total Shares Outstanding of 0.00% as of Jul. 12, 2026. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on PharmaEngine and its competitors.
Is PharmaEngine's Float Percentage Of Total Shares Outstanding too high?
PharmaEngine's current Float Percentage Of Total Shares Outstanding is 0.00%. Overall, PharmaEngine has a GF Score™ of 79/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does PharmaEngine's Float Percentage Of Total Shares Outstanding compare to VRTX and REGN?
PharmaEngine's Float Percentage Of Total Shares Outstanding of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Float Percentage Of Total Shares Outstanding for a Biotechnology company?
A good Float Percentage Of Total Shares Outstanding depends on the Biotechnology industry context. However, Float Percentage Of Total Shares Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Float Percentage Of Total Shares Outstanding mean?
A high Float Percentage Of Total Shares Outstanding can signal that a stock is expensive relative to its fundamentals. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on PharmaEngine and its competitors. PharmaEngine's current Float Percentage Of Total Shares Outstanding is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PharmaEngine stock overvalued right now?
Based on GuruFocus' analysis, PharmaEngine (ROCO:4162) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$115.42, compared to a current price of NT$64.50 — trading 44.1% below its estimated fair value. The current Float Percentage Of Total Shares Outstanding is 0.00%. PharmaEngine's overall GF Score™ is 79/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Float Percentage Of Total Shares Outstanding calculated?
Float Percentage Of Total Shares Outstanding is calculated from a company's financial statements. For PharmaEngine (ROCO:4162), the current Float Percentage Of Total Shares Outstanding is 0.00% as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is PharmaEngine (ROCO:4162) Overvalued in 2026?

Based on GuruFocus' analysis, PharmaEngine stock appears to be undervalued. The current stock price of NT$64.50 is trading 44.1% below its estimated GF Value™ of NT$115.42. GuruFocus considers PharmaEngine to be Significantly Undervalued.

Key valuation signals for ROCO:4162:

  • Float Percentage Of Total Shares Outstanding: 0.00%
  • GF Value™: NT$115.42 vs. price of NT$64.50 (44.1% below fair value)
  • GF Score™: 79/100 with 3 warning signs

No single metric tells the full story. See the ROCO:4162 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

PharmaEngine Business Description

Address No. 10, Minsheng East Road, 11th Floor, Section 3, Taipei, TWN, 104
PharmaEngine Inc is a biopharmaceutical company engaged in the development of new drugs and therapeutic drugs for cancer. It is a specialty pharma company that adopts the no research, development-only model and the networked pharma model for new drug development. Its key products and pipeline projects include ONIVYDE, a treatment for metastatic pancreatic cancer approved in multiple markets, as well as oncology candidates such as PEP07 and PEP08. It generates revenue from the sales of goods.
79GF Score

Get the complete analysis for ROCO:4162

Float Percentage Of Total Shares Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$64.50
Price
NT$115.42
GF Value